High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease
Annals of Clinical and Translational Neurology · 2023
DOI: 10.1002/acn3.51873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2023. Verfasst von Samir Abu-Rumeileh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. Hauptthemen laut MEDLINE: Creutzfeldt-Jakob Syndrome. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Fondation Thierry Latran.
Abstract (Originalsprache)
Beta‐synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. Here we analysed its accuracy in the discrimination between sporadic Creutzfeldt–Jakob disease ( n = 150) and non‐prion rapidly progressive dementias ( n = 106). In cerebrospinal fluid, beta‐synuclein performed better than protein 14‐3‐3 (AUC 0.95 vs. 0.89) and, to a lesser extent, than total tau (AUC 0.92). Further, the diagnostic value of plasma beta‐synuclein (AUC 0.91) outperformed that of plasma tau (AUC 0.79) and neurofilament light chain protein (AUC 0.65) and was comparable to that of cerebrospinal fluid biomarkers. Beta‐synuclein might represent the first highly accurate blood biomarker for the diagnosis of sporadic Creutzfeldt–Jakob disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
- Department of Neurology, Ulm University Hospital, Ulm, Germany.
- German Center for Neurodegenerative Diseases (DZNE e.V.), Ulm, Germany.
- Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
ORCID-Profile: Samir Abu-Rumeileh, Lorenzo Barba, Piero Parchi
Förderung
- Ministero della Salute
- Fondation Thierry Latran
Zitieren
APA
Abu-Rumeileh, S., Halbgebauer, S., Bentivenga, G. M., Barba, L., Baiardi, S., Mastrangelo, A., Oeckl, P., Steinacker, P., Mammana, A., Capellari, S., Otto, M., & Parchi, P. (2023). High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51873
Vancouver
Abu-Rumeileh S, Halbgebauer S, Bentivenga GM, Barba L, Baiardi S, Mastrangelo A, et al. High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease. Annals of Clinical and Translational Neurology. 2023. doi:10.1002/acn3.51873
BibTeX
@article{AbuRumeileh2023,
author = {Abu-Rumeileh, Samir and Halbgebauer, Steffen and Bentivenga, Giuseppe Mario and Barba, Lorenzo and Baiardi, Simone and Mastrangelo, Andrea and Oeckl, Patrick and Steinacker, Petra and Mammana, Angela and Capellari, Sabina and Otto, Markus and Parchi, Piero},
title = {High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
doi = {10.1002/acn3.51873}
}
EUVIMED